Potential pandemics caused by artificial intelligence are being targeted by the drug-design efforts of startup Red Queen Bio. The company utilizes artificial intelligence to engineer antibody treatments for novel pathogens in an attempt to ensure that medications exist before the diseases themselves are created.

This preemptive strategy focuses on the risk that future iterations of AI could eventually be used to develop biological threats. By identifying and solving for these risks in advance, Red Queen Bio intends to mitigate the danger of man-made pathogens engineered by software.